AtaiBeckley (NASDAQ:ATAI) has officially completed its redomiciliation from the Netherlands to Delaware, finalizing a corporate overhaul that follows the recent strategic combination of atai Life Sciences and Beckley Psytech.
The transition, which became effective after the market close on Dec. 30, 2025, saw all outstanding ordinary shares of the former Dutch parent entity exchanged on a one-for-one basis for common stock in the new Delaware-incorporated AtaiBeckley Inc.
The move was overwhelmingly supported by shareholders, receiving approximately 99% of votes cast during an extraordinary general meeting in November.
By moving its legal home to the U.S., the clinical-stage biopharmaceutical company aims to simplify its corporate structure and achieve significant long-term cost savings.
Management noted that the new structure provides a closer alignment with its Nasdaq listing and a shareholder base that is predominantly U.S.-based, while also streamlining financial reporting and reducing the regulatory complexities associated with dual-jurisdiction compliance.
The corporate relocation caps a transformational year for the company.
Following its merger with Beckley Psytech in late 2025, AtaiBeckley has emerged as a leader in the psychedelic therapeutics space, recently gaining inclusion in the Nasdaq Biotechnology Index.
The company is currently advancing a high-priority pipeline, including BPL-003—a nasal spray for treatment-resistant depression that recently received FDA Breakthrough Therapy designation.
AtaiBeckley’s common stock will continue to trade under the ticker "ATAI" without interruption.